农林牧渔/动物保健Ⅱ 生物股份（600201.SH） 非瘟亚单位疫苗临床试验获批，创新龙头成长动能强 2025 年 07 月 18 日 投资评级：买入（维持） | 日期 | 2025/7/17 | | --- | --- | | 当前股价(元) | 9.53 | | 一年最高最低(元) | 9.53/5.62 | | 总市值(亿元) | 106.77 | | 流通市值(亿元) | 106.77 | | 总股本(亿股) | 11.20 | | 流通股本(亿股) | 11.20 | | 近 3 个月换手率(%) | 156.32 | 股价走势图 -20% 0% 20% 40% 60% 2024-07 2024-11 2025-03 生物股份 沪深300 数据来源：聚源 相关研究报告 《业绩短期承压，持续创新厚积薄发 —公司信息更新报告》-2025.4.27 《业绩短期承压，新品储备充足持续 成长—公司信息更新报告》-2024.11.3 《业绩韧性十足创新驱动发展，新品 多点开花持续成长—公司信息更新报 告》-2024.9.1 陈雪丽（分析师） 王高展（分析师） chenxueli@kysec.cn 证书编号：S0 ...

Core Viewpoint - The stock of Jinyu Biotechnology Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over three consecutive trading days from July 15 to July 17, 2025, triggering the abnormal fluctuation standards set by the Shanghai Stock Exchange [2][3]. Group 1: Stock Trading Abnormalities - The stock price of Jinyu Biotechnology rose significantly, with a cumulative increase of over 20% during the specified trading days [2][3]. - The company confirmed that its production and operational conditions remain normal, with no significant changes in the external business environment [4]. Group 2: Financial Performance - The company anticipates a net profit attributable to shareholders of between 57 million to 70 million yuan for the first half of 2025, representing a decrease of 52.92 million to 65.92 million yuan compared to the same period last year, which is a year-on-year decline of 43.05% to 53.63% [4]. - The expected net profit after deducting non-recurring gains and losses is projected to be between 30 million to 44 million yuan, reflecting a decrease of 63.86 million to 77.86 million yuan year-on-year, a decline of 59.21% to 72.19% [4]. Group 3: Major Events and Developments - The company’s wholly-owned subsidiary, Jinyu Baoling, received a clinical trial approval for an African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs [5][12]. - The vaccine development has involved a cumulative investment of approximately 64 million yuan [13]. Group 4: Shareholder and Management Actions - The company’s major shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., confirmed that there are no undisclosed significant matters related to the company, including major asset restructuring or significant transactions [5][8]. - There were no stock trading activities by the company’s directors, senior management, or major shareholders during the period of abnormal stock price fluctuations [8].

经公司书面征询本公司第一大股东内蒙古金宇生物控股有限公司（以下简 称"生物控股"），截至本公告披露日，除在指定信息披露媒体及上海证券交易所 网站上已公开披露的信息外，不存在应披露而未披露的信息。 公司于本公告披露日同日披露了《金宇生物技术股份有限公司关于获得兽 用生物制品临床试验批件的公告》，全资子公司金宇保灵生物药品有限公司（以下 简称"金宇保灵"）收到农业农村部颁发的非洲猪瘟亚单位疫苗临床试验批件。兽 用生物制品在获得临床试验批准后，需要完成临床试验并申报注册，经农业农村部 审评、审批通过获得新兽药证书、兽药产品批准文号后方可上市销售。 证券代码：600201 证券简称：生物股份 公告编号：临2025-044 金宇生物技术股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 金宇生物技术股份有限公司（以下简称"公司"）股票于 2025 年 7 月 15 日、7 月 16 日、7 月 17 日连续 3 个交易日收盘价格涨幅偏离值累计超过 20%。触 及《上海证券交易所交易规则》规 ...

证券代码：600201 证券简称：生物股份 公告编号：临2025-043 金宇生物技术股份有限公司 疫苗产品从前期研发到上市销售整个周期较长，且由于非洲猪瘟病毒免疫机制 的复杂性，本项目在临床试验客观上存在一定的失败风险，项目研究开发进度、技 术成果、后期产业化应用进程等尚存在一定不确定性。根据我国《兽药管理条例》 和《兽药注册办法》的规定，兽用生物制品在获得临床试验批准后，需要完成临床 试验并申报注册，经农业农村部审评、审批通过获得新兽药证书、兽药产品批准文 项目名称 非洲猪瘟亚单位疫苗临床试验 受理号 07020020250417-1 审批结论 同意申请单位在有效期限内在批准的试验地点进行临床试验 申请人 中国科学院生物物理研究所、国药集团动物保健股份有限公 司、金宇保灵生物药品有限公司、中牧实业股份有限公司、 广东蓝玉生物科技有限公司、中国科学院武汉病毒研究所 临床试验承担单位 金宇保灵生物药品有限公司 一、 临床批件主要内容 号后方可上市销售。公司将密切关注后续进展并及时履行信息披露义务，敬请广大 投资者理性投资，注意风险。 特此公告。 金宇生物技术股份有限公司 董 事 会 关于获得兽用生物制品临床试 ...

Core Viewpoint - The company has received clinical trial approval for its African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs, marking a significant step in its vaccine development efforts [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., has been granted the clinical trial approval (Approval No: 2025058) for the African swine fever vaccine [1] - The vaccine is specifically designed to prevent African swine fever virus infections, indicating a targeted approach to addressing this critical issue in the livestock industry [1] - The company has invested approximately 64 million yuan in research and development for this vaccine in collaboration with research institutions since 2023 [1] Group 2: Clinical Trial Process - The clinical trials will be conducted at Jinyu Baoling, and the vaccine must complete these trials and undergo registration application before it can be marketed and sold [1] - Approval from regulatory bodies is required after the completion of clinical trials, highlighting the importance of compliance in the pharmaceutical development process [1]

Group 1 - The company announced that its wholly-owned subsidiary, Jinyu Baoling, received clinical trial approval for an African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs [1] - The vaccine is jointly developed by the Institute of Biophysics of the Chinese Academy of Sciences and China National Pharmaceutical Group Animal Health Co., Ltd., with Jinyu Baoling as the clinical trial undertaking unit [1] - The total research and development investment for the project is approximately 64 million yuan [1] Group 2 - Due to the complexity of the immune mechanism of the African swine fever virus, there is a risk of failure in the clinical trials [1] - The vaccine must complete clinical trials and obtain registration approval before it can be marketed and sold [1] - The company will monitor subsequent developments and fulfill its information disclosure obligations [1]

Group 1: Stock Performance - Zhejiang Zhenyuan and Asia-Pacific Pharmaceutical both achieved a 2-day limit-up with increases of 10.01% and 9.98% respectively, driven by innovation in pharmaceuticals [2] - Chengdu XianDao saw a first board listing with a significant rise of 20.02%, attributed to innovative drug developments [2] - TaiJing Technology and YanHua Intelligent both recorded first board listings with increases of 9.97% and 9.94%, linked to Huawei's influence in robotics [5] Group 2: AI and Robotics - Nvidia's CEO suggested that Huawei's AI chips could potentially replace Nvidia's offerings, indicating a competitive shift in the AI chip market [4] - The domestic robotics industry is gaining traction with significant orders being awarded, highlighting its importance in national competition [7] Group 3: Market Trends - The light communication sector is expected to see sustained growth due to high demand in both domestic and international markets, with performance likely to continue improving [13] - The low-altitude economy is gaining attention, with a notable $1 billion procurement agreement signed for eVTOL aircraft, indicating growth potential in this sector [17] Group 4: Consumer and Retail - The Chinese government is implementing measures to boost consumer spending, which is expected to positively impact the retail sector [21] - Companies like Guoguang Chain and Hanshang Group have seen first board listings with increases of 9.98% and 9.97%, reflecting the positive sentiment in the retail market [23] Group 5: Solar and Food & Beverage - The price of polysilicon has increased by 12.4% week-on-week, indicating a rising trend in the solar industry [24] - The food and beverage sector is also benefiting from government initiatives aimed at enhancing consumer demand, with companies like Huangshi Group seeing a 10.10% increase [26]

Group 1 - The core viewpoint of the articles highlights the rebound in CBOT soybean futures due to anticipated increases in U.S. soybean export demand, particularly following Indonesia's commitment to purchase $4.5 billion worth of U.S. agricultural products [1] - The domestic soybean meal supply is currently ample, which is suppressing upward price movement, while downstream inventory levels are nearing saturation due to previous active replenishment [1] - The A-share market saw a rise in the livestock sector, with notable increases in stocks such as Bio-Group (+8.31%), Luo Niu Shan (+2.09%), and others, indicating a positive market sentiment towards the livestock industry [1] Group 2 - The soybean meal ETF (159985) is recognized not only as a standalone investment but also for its long-term investment value in asset allocation, inflation hedging, and roll yield [2] - Soybean meal has a low correlation with the stock market, suggesting that it can be a strategic long-term allocation even if short-term price increases are uncertain [2] - As the largest production variety among 12 oilseed meal feed types, soybean meal has a solid spot market foundation, enhancing its investment appeal [2]

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

机构龙虎榜净买卖个股 机构专用席位净买入金额最多的是华宏科技，该股今日收盘涨停，全天换手率为27.83%，成交额为 19.19亿元。因日涨幅偏离值达9.90%上榜龙虎榜，前五大买卖营业部中有5家机构专用席位，为买一、 买二、买四、买五、卖五，合计净买入11281.13万元。资金流向方面，该股全天资金净流出1.95亿元。 塞力医疗，今日收盘下跌3.26%，全天换手率为31.83%，成交额为13.06亿元。因日换手率达31.12%上榜 龙虎榜，前五大买卖营业部中有1家机构专用席位，为买一，合计净买入7426.30万元。资金流向方面， 该股全天资金净流出156.42万元。 7月16日沪指下跌0.03%，盘后龙虎榜数据显示，机构现身25只个股龙虎榜，净买入11只，净卖出14 只。深沪股通席位出现在12只个股龙虎榜。 证券时报·数据宝统计显示，7月16日机构专用席位现身25只个股龙虎榜，合计净卖出10.15亿元。个股来 看，净买入11只，净卖出14只。 7月16日机构龙虎榜净买卖个股 | 代码 | 简称 | 当日涨跌幅（%） | 当日换手率（%） | 机构净买入（万元） | | --- | --- | --- | -- ...